Scinovex
articleTop 1% cited

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

Arthritis & Rheumatism · 1998 · Vol. 41(9) · pp. 1552–1563
Ravinder N. MainiFerdinand C. BreedveldJoachim R. KaldenJosef S SmolenDiana DavisJ. D. MacfarlaneChristian AntoniBurkhard F. LeebMichael J. ElliottJames N. WoodyT SchaibleMarc Feldmann

Abstract

Multiple infusions of cA2 were effective and well tolerated, with the best results occurring at 3 and 10 mg/kg either alone or in combination with MTX in approximately 60% of patients with active RA despite therapy with low-dose MTX. When cA2 at 1 mg/kg was given with low-dose MTX, synergy was observed. The results of the trial provide a strategy for further evaluation of the efficacy and safety of longer-term treatment with cA2.

Rheumatoid Arthritis Research and TherapiesMonoclonal and Polyclonal Antibodies ResearchSystemic Lupus Erythematosus ResearchMedicinePlaceboRheumatoid arthritisMethotrexateGastroenterologyPharmacokineticsInternal medicineArthritisInfliximabSurgery

MeSH terms

InfliximabAdultAgedAntibodies, MonoclonalArthritis, RheumatoidDouble-Blind MethodDrug Therapy, CombinationFemaleHumansInfusions, IntravenousMaleMethotrexateMiddle AgedSafetyTumor Necrosis Factor-alpha
Citations
1,638
FWCI
57.61
field-weighted impact
References
30
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.